Bulgaria’s Sopharma 9-mo non-cons net profit falls 2.7%

Its earnings before interest, taxes, depreciation and amortisation (EBITDA) went down by 5.7% on the year to 42.09 million levs through September, Sopharma said in a statement filed with the Bulgarian Stock Exchange (BSE).

Sales revenue rose by an annual 2.2% to 159.05 million levs in the January-September period, as Russia, Bulgaria and Ukraine were the company's main markets, accounting for 80% of Sopharma's total sales revenue in the period under review.

Sopharma’s biggest annual increase in terms of sales revenue was generated on the Polish market, where sales jumped 289% to 6.28 million levs.

The company’s nine-month sales revenue on the domestic market, however, fell by 10% on the year to 41.7 million levs.

Earnings per share slipped to 0.27 levs in the period under review from 0.28 levs a year earlier.

Sopharma (www.sopharma.bg) exports its output to 28 countries. It employed a total of 1,865 people at the end of September.

Blue-chip Sopharma's shares were traded 2.89% lower at 2.32 levs at 1430 GMT on the Sofia bourse.

(1 euro = 1.95583 Bulgarian levs)